Dr. Reddy's Laboratories Ltd. Q3 FY2026 results: revenue ₹8,753 crore, up 4.4% on the year
Dr. Reddy's Laboratories Ltd. (DRREDDY) reported consolidated revenue from operations of ₹8,753 crore for Q3 FY2026, the quarter ended 31 December 2025, up 4.4% on the same quarter a year earlier. Profit after tax was ₹1,190 crore, down 15.3% on the year, and earnings per share ₹14.53. The figures are the company's own, from the un-audited results it filed with NSE on 21 January 2026.
The quarter, against the one before and a year earlier
| Line | Q3 FY2026 | Q2 FY2026 | Q3 FY2025 | Change on the year |
|---|---|---|---|---|
| Revenue from operations | 8,753 | 8,828 | 8,381 | +4.4% |
| Other income | 269 | 324 | 150 | +79.0% |
| Total income | 9,022 | 9,152 | 8,531 | +5.8% |
| Cost of materials consumed | 1,826 | 1,441 | 1,453 | +25.7% |
| Purchases of stock-in-trade | 1,542 | 1,746 | 1,051 | +46.8% |
| Changes in inventories | -272 | -64 | 78 | n/a |
| Employee benefit expense | 1,588 | 1,452 | 1,366 | +16.2% |
| Finance costs | 94 | 91 | 82 | +15.5% |
| Depreciation, depletion and amortisation | 521 | 505 | 471 | +10.5% |
| Other expenses | 2,155 | 2,175 | 2,160 | -0.2% |
| Total expenses | 7,481 | 7,414 | 6,661 | +12.3% |
| Profit before exceptional items and tax | 1,541 | 1,738 | 1,870 | -17.6% |
| Exceptional items | 0 | 0 | 0 | n/a |
| Profit before tax | 1,541 | 1,738 | 1,870 | -17.6% |
| Current tax | 207 | 185 | 533 | -61.1% |
| Deferred tax | 146 | 223 | -63 | n/a |
| Total tax | 354 | 408 | 470 | -24.8% |
| Profit after tax | 1,190 | 1,337 | 1,404 | -15.3% |
| Attributable to owners of the parent | 1,210 | 1,347 | 1,414 | -14.4% |
| Other comprehensive income | 177 | 112 | -202 | n/a |
| Total comprehensive income | 1,367 | 1,449 | 1,202 | +13.7% |
| EPS, basic | ₹14.53 | ₹16.18 | ₹16.97 | -14.4% |
| EPS, diluted | ₹14.52 | ₹16.17 | ₹16.94 | -14.3% |
₹ crore except per share.
Segments, Q3 FY2026
| Segment | Revenue ₹ crore | Share of segment revenue | Result ₹ crore | Result over revenue |
|---|---|---|---|---|
| a) Global Generics | 7,957 | 89.2% | 4,541 | 57.1% |
| b) Pharmaceutical Services and Active Ingredients | 947 | 10.6% | 136 | 14.4% |
| c) Others | 15 | 0.2% | 4 | 28.5% |
Segment revenue and segment result as the company filed them, before inter-segment eliminations; share and result over revenue are arithmetic on those.
Quarterly results, the last 12 quarters
| Q2 FY2024 | Q3 FY2024 | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Q4 FY2026 | Q1 FY2027 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 6,903 | 7,237 | 7,114 | 7,696 | 8,038 | 8,381 | 8,528 | 8,572 | 8,828 | 8,753 | 7,546 | 8,100 |
| Expenses | 5,305 | 5,627 | 5,710 | 6,007 | 6,434 | 6,661 | 7,051 | 6,958 | 7,414 | 7,481 | 7,827 | 7,902 |
| Operating profit | 2,008 | 2,023 | 1,831 | 2,130 | 2,076 | 2,273 | 1,998 | 2,174 | 2,010 | 1,887 | 382 | 860 |
| OPM % | 29% | 28% | 26% | 28% | 26% | 27% | 23% | 25% | 23% | 22% | 5% | 11% |
| Other income | 315 | 216 | 198 | 187 | 308 | 150 | 522 | 290 | 324 | 269 | 475 | 355 |
| Interest | 35 | 39 | 59 | 60 | 76 | 82 | 66 | 83 | 91 | 94 | 106 | 126 |
| Depreciation | 376 | 374 | 368 | 381 | 397 | 471 | 455 | 476 | 505 | 521 | 557 | 537 |
| Exceptional items | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 1,912 | 1,826 | 1,602 | 1,877 | 1,911 | 1,870 | 2,000 | 1,905 | 1,738 | 1,541 | 195 | 552 |
| Tax % | 23% | 25% | 18% | 26% | 30% | 25% | 21% | 26% | 23% | 23% | -11% | 21% |
| Net profit | 1,482 | 1,381 | 1,310 | 1,392 | 1,342 | 1,404 | 1,587 | 1,410 | 1,337 | 1,190 | 221 | 436 |
| EPS in ₹ | ₹89.09 | ₹82.94 | ₹78.66 | ₹83.61 | ₹15.08 | ₹16.97 | ₹19.12 | ₹17.04 | ₹16.18 | ₹14.53 | ₹2.65 | ₹5.33 |
| Filing | NSE | NSE | NSE | NSE | NSE | NSE | Filing | Filing | Filing | Filing | Filing | Filing |
₹ crore except per share, consolidated, as filed with the exchange. Operating profit is sales less the expenses other than interest and depreciation, OPM is that over sales, and tax % is tax over profit before tax: arithmetic on the filed lines; everything else is as filed. Quarters before December 2024 are from the exchange's earlier results feed, which carries the filed lines without the filing itself; the column links to the exchange's page for the company. EPS is as filed for each quarter. A split or a bonus issue changes the share count, so quarters before it are on the old count.
Source
Un-audited consolidated results for the quarter ended 31 December 2025, filed with NSE on 21 January 2026: the result statement. All of Dr. Reddy's Laboratories Ltd.'s results: NSE company page.
The same record on your computer
GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.